Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure

dc.contributor.authorRodrigues, João Paulo Vilela
dc.contributor.authorCampos, Guilherme Rodrigues Fernandes [UNESP]
dc.contributor.authorBittar, Cintia [UNESP]
dc.contributor.authorMartinelli, Ana De Lourdes Candolo
dc.contributor.authorCampos, Marília Silveira De Almeida
dc.contributor.authorPereira, Leonardo Régis Leira
dc.contributor.authorRahal, Paula [UNESP]
dc.contributor.authorSouza, Fernanda Fernandes
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.date.accessioned2023-07-29T11:15:02Z
dc.date.available2023-07-29T11:15:02Z
dc.date.issued2023-01-23
dc.description.abstractThe chronic hepatitis C (CHC) treatment is currently based on the use of direct-acting antivirals (DAAs), and patients infected with hepatitis C virus genotype 3 (GT3) have emerged as a more difficult-to-cure population. The NS5A inhibitor daclatasvir (DCV) and sofosbuvir (SOF), an NS5B viral polymerase inhibitor, are among the drugs that compose more effective and safer treatment regimens. The virus genetic variability is related to resistance-associated substitutions (RASs) that adversely impact DAAs effectiveness. The aims of this study were to analyze the association of NS5A and NS5B RASs and other clinical factors with DAAs regimens effectiveness in patients with GT3 CHC infection. This was a prospective cohort study performed in a Brazilian university hospital. Individuals older than 18 years with GT3 CHC treated with SOF + DCV ± ribavirin (RBV) or SOF + peginterferon (PEG) + RBV were included. Blood samples were collected at baseline and post-treatment. A total of 121 patients were included. Sustained virological response rates were 87.6% for the SOF + DCV ± RBV group and 80.0% for the SOF + PEG + RBV arm. Cirrhosis, prior treatment with interferon/PEG + RBV, and baseline NS5A RAS were associated with higher risk of treatment failure. The NS5A analysis suggested that A30K, Y93H, and RAS at site 62 were related to failure. Interestingly, a likely compensatory effect was shown between A30K and A62T. Emergence of Y93H was always associated with RAS at position 62. The RASs dynamics comprehension is an important tool to indicate more effective treatment for GT3 patients.en
dc.description.affiliationUniversidade de São Paulo, Faculdade de Medicina de Ribeirão Preto
dc.description.affiliationUniversidade Estadual Paulista, Instituto de Biociências, Letras e Ciências Exatas
dc.description.affiliationUniversidade de São Paulo, Faculdade de Ciências Farmacêuticas de Ribeirão Preto
dc.description.affiliationUnespUniversidade Estadual Paulista, Instituto de Biociências, Letras e Ciências Exatas
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIdFAPESP: Scholarship Grants 2016/03807-0
dc.description.sponsorshipIdFAPESP: Project Grant 2017/22927-0
dc.format.extent-
dc.identifierhttp://dx.doi.org/10.1016/j.bjid.2022.102717
dc.identifier.citationBrazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 26, n. 6, p. -, 2023.
dc.identifier.doi10.1016/j.bjid.2022.102717
dc.identifier.fileS1413-86702022000600203.pdf
dc.identifier.issn1413-8670
dc.identifier.issn1678-4391
dc.identifier.scieloS1413-86702022000600203
dc.identifier.urihttp://hdl.handle.net/11449/244918
dc.language.isoeng
dc.publisherBrazilian Society of Infectious Diseases
dc.relation.ispartofBrazilian Journal of Infectious Diseases
dc.rights.accessRightsAcesso aberto
dc.sourceSciELO
dc.subjectHepatitis C, Chronicen
dc.subjectHepacivirusen
dc.subjectAntiviral agentsen
dc.subjectDrug resistance, Viralen
dc.titleSelection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressureen
dc.typeArtigo
unesp.author.orcid0000-0002-5785-1418[1]
unesp.author.orcid0000-0003-1118-8486[2]
unesp.author.orcid0000-0002-2048-4589[3]
unesp.author.orcid0000-0003-2420-4641[5]
unesp.author.orcid0000-0002-2369-7686[8]

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
S1413-86702022000600203.pdf
Tamanho:
540.35 KB
Formato:
Adobe Portable Document Format